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South Africa has one of the highest rates of tuberculosis (TB) 
in the world.  It is ranked ninth in the world in terms of the 
number of cases, and has an estimated incidence of 558 cases 
per 100 000 population.1 The TB burden is exacerbated by a 
high incidence of HIV infection.2 Between 28.2% and 71.9% of 
TB cases in the different provinces are estimated to be HIV-
positive.3 The Eastern Cape suffers a high burden of TB, having 
a higher-than-national average incidence and the second-
highest case load of the 9 provinces.2  
Multidrug-resistant TB (MDR-TB), defined as resistance to 
at least rifampicin and isoniazid, is a threat to successful TB 
control.4 A survey of MDR-TB in South Africa3 reported a mean 
rate of 1.6% in new cases and 6.6% in previously treated cases. 
South Africa is reported to have at least 6 000 new cases of 
MDR-TB per year.5  
Patients with MDR-TB are at a high risk of treatment 
failure on short-course chemotherapy.6 Conventional drug 
susceptibility testing for TB has a long turnaround time of 
several weeks to months, which delays diagnosis of MDR-
TB patients.  Earlier identification of patients with MDR-TB 
and appropriate treatment is expected to improve individual 
patient outcomes and overall disease control.  
Phage amplification (FASTPlaque) technology7,8 (Biotec 
Laboratories, Ipswich, UK)  is a rapid method for both the 
diagnosis of TB9-12) and rifampicin susceptibility testing.13-15  
This technology utilises mycobacteriophage (phage; bacterial 
viruses) to detect viable Mycobacterium tuberculosis complex 
organisms. The FASTPlaque technology has been previously 
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Background and objectives. Patients with multidrug-resistant 
(MDR) tuberculosis (TB) are at high risk of treatment failure.  
It is anticipated that early identification of MDR-TB and 
appropriate treatment will improve patient outcome and 
disease control.  We evaluated the rapid detection of rifampicin 
resistance in previously treated TB patients, directly from acid-
fast bacilli (AFB)-positive sputum using a phage-based test, 
FASTPlaque-Response (Biotec Laboratories Ltd, Ipswich, UK).  
The ability of rifampicin resistance to predict MDR-TB was also 
determined.
Design. A prospective study was done comparing performance 
of the rapid phage test with conventional culture and drug 
susceptibility testing (DST) in AFB-positive TB patients.  
Setting. Five primary health clinics and one TB referral centre 
in the Port Elizabeth Metropolitan area, Eastern Cape.
Outcome measures. Sensitivity, specificity and overall accuracy 
of the phage test were determined compared with gold 
standard culture and DST.  Discrepant results were resolved 
by molecular detection of mutations conferring rifampicin 
resistance.  The proportion of rifampicin-resistant strains that 
were MDR was also determined.
Results. Previously treated patients were at a high risk of MDR-
TB (35.7%).  Sensitivity, specificity and overall accuracy of 
FASTPlaque-Response for rifampicin resistance determination 
were 95.4% (95% confidence interval (CI): 91.0 - 99.8%), 
97.2% (95% CI: 94.5 - 99.9%) and 96.5% (95% CI: 94.1 - 98.9%) 
respectively compared with conventional DST (unresolved), 
calculated for specimens that had both FASTPlaque-Response 
and conventional DST results available.  FASTPlaque-Response 
results were available in 2 days instead of 28 - 85 days with 
conventional DST.  However, only 70.6% of FASTPlaque-
Response results were interpretable compared with 86.3% of 
conventional DST results.  The majority (95.5%) of rifampicin-
resistant strains were MDR-TB.
Conclusions. Rapid detection of rifampicin resistance using 
FASTPlaque-Response could contribute to improved 
management of patients at risk of MDR-TB, such as previously 
treated patients.  However, improvement in control of 
specimen-related contamination is needed to ensure that 
a higher proportion of FASTPlaque-Response results are 
interpretable.  Where indicated, early modification of 
therapy could improve patient prognosis and reduce disease 
transmission.
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evaluated in South Africa.9,12-14 as well as in other high-burden 
countries.10,13,15
This study sought to evaluate the performance of phage 
amplification technology in detecting rifampicin resistance 
directly from acid-fast bacilli (AFB) smear-positive sputum, in 
a population of patients previously treated for TB (re-treatment 
cases), who are at increased risk of MDR-TB.  The utility 
of rifampicin resistance as an indicator for MDR-TB in this 
population was also determined.
Material and methods
Patients
Patients were recruited at 6 clinics (5 primary health care 
facilities and 1 TB referral centre) in the Port Elizabeth and 
Uitenhage Metropolitan area in the Eastern Cape between 
15 September 2003 and 26 May 2004.  Symptomatic patients 
presenting at the clinics were tested according to TB control 
programme guidelines.16 Patients who had been previously 
treated for TB and whose sputum was found to be AFB smear-
positive (re-treatment cases) were selected for inclusion in 
this study.  Patients were categorised as treatment failure 
(RF), treatment interruption (RI), previously cured (RC), or 
completed previous treatment (RT).  The study was subject to 
ethical review by the South African Medical Research Council 
and World Health Organization (WHO) committees.  Written 
informed consent in either English, Xhosa or Afrikaans was 
obtained from all patients.  
Sample size
Published data estimated approximately 8% MDR-TB in 
previously treated patients in the Eastern Cape.3 Therefore, 
a sample size of 500 smear-positive patients was estimated 
to include at least 40 rifampicin-resistant specimens. Forty 
rifampicin-resistant TB strains would allow estimation of the 
true sensitivity of the test (ability to detect true rifampicin 
resistance) to be at least 95% compared with the conventional 
method, at a significance level of 0.05, and a reliability level of 
7%. Based on previous studies,13 results of approximately 85% 
of conventional and phage-based methods were anticipated to 
be available for analysis (remaining results were expected to 
be unavailable because of contamination or un-interpretable 
results). Therefore a sample size of at least 590 smear-positive 
specimens was set for the study.
Laboratory testing
Before commencing treatment an additional sputum specimen 
was collected from re-treatment patients who had a recent 
positive smear result (usually within the previous week) 
and had returned to the clinic to commence the standard 
re-treatment regimen.16 Specimens were stored refrigerated 
for a maximum of 3 days before transport to the laboratory 
according to the manufacturer’s recommendations.17 Specimens 
were transported by courier to the laboratory in Cape Town 
for testing by smear microscopy, FASTPlaque-Response, 
conventional indirect drug susceptibility testing (DST) and 
molecular testing.  
On receipt a direct smear was prepared from each specimen, 
stained using the Ziehl-Neelsen method and examined at  
x 1 000 magnification.  Smears were graded according to the 
International Union Against Tuberculosis and Lung Disease 
(IUATLD) guidelines,18 as followed by the National Health 
Laboratory Service (NHLS).  Specimens with a smear grading 
of 1+ or more were included in the study.  
Sputum specimens were decontaminated using the 
N-acetyl-L-cysteine-sodium hydroxide (NALC-NaOH) 
method.19 Following centrifugation, the pellet was suspended 
in approximately 1.5 ml of phosphate buffer pH 6.8.  Two 
portions of 0.1 ml were inoculated on Lowenstein-Jensen (LJ) 
medium and 0.2 ml onto a selective Middlebrook 7H11 plate.  
A 0.5 ml portion of the processed sediment was removed for 
DNA sequencing.
Cultures were incubated for up to 8 weeks in a 5 - 10% 
CO2 atmosphere.  Positive cultures were confirmed as M. 
tuberculosis complex by use of Ziehl-Neelsen staining and 
p-nitrobenzoic acid (PNB) testing. M. tuberculosis complex 
does not grow within 3 days, is non-pigmented and does not 
grow on PNB-containing medium.  Conventional indirect 
DST was performed using a modified proportion method on 
Middlebrook 7H11 medium containing 1.0 µg/ml rifampicin 
and 0.2 µg/ml isoniazid respectively.19 Isolates were classified 
as resistant if there was 1% or more growth on the drug-
containing medium compared with the control.  
FASTPlaque-Response test
FASTPlaque-Response tests were provided by Biotec 
Laboratories Ltd. (Ipswich, UK) and were performed according 
to the manufacturer’s instructions.17 Briefly, the residual 
specimen was washed in medium and then split, with one 
portion incubated overnight with rifampicin, and the other 
incubated in drug-free medium. The viability of the M. 
tuberculosis strain was assessed by its ability to support phage 
replication (production of plaques) after incubation with 
rifampicin.  Specimen results were considered valid if 100 
plaques or more were observed on the rifampicin-free (RIF–) 
plate.  Strains were determined to be susceptible to rifampicin 
if less than 50 plaques resulted from the rifampicin-containing 
sample (RIF+), and rifampicin-resistant if 50 plaques or more 
were obtained.  
Discrepant results
For any specimens in which the FASTPlaque-Response and 
the conventional drug susceptibility result disagreed, both 
methods were repeated.  FASTPlaque testing was performed 
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from the positive culture.  In addition, molecular testing 
for rifampicin resistance was performed on all samples.20 
These results were used to confirm the presence of mutations 
related to rifampicin resistance in specimens in which there 
was a discrepancy between the FASTPlaque-Response and 
conventional DST result.  
Phage-based testing was performed on cultures of all 
strains in which less than 100 plaques were obtained on the 
FASTPlaque-Response test but the smear and culture were 
both positive.  This was to determine whether the phage was 
able to infect these particular strains of TB. The FASTPlaque-
Response procedure was followed as described earlier, except 
that the rifampicin solution used for indirect testing was half 
the concentration used in the direct test (final concentration, 
5 µg/ml).  Testing directly from sputum requires a higher 
concentration of rifampicin because of binding and inactivation 
of rifampicin in the complex sputum matrix, to allow an 
equivalent active drug concentration.  Interpretation of results 
was as previously described.14
Results
A total of 573 specimens were received from 556 patients.  Six 
specimen containers were empty on receipt at the laboratory, 
and 8 specimens were more than 4 days old and had been 
stored inappropriately before shipment to the laboratory 
and were therefore excluded from testing. One hundred and 
seventy smear-negative specimens and 25 scanty positive 
specimens were received and were excluded from the study.  
Of the remaining 364 specimens included in the study, 142, 
125 and 97 specimens were 1+, 2+ and 3+ smear-positive 
respectively.   Results of 50 specimens (13.7%) were unavailable 
using the conventional method because of failure to grow, 
contamination of the culture, or indirect susceptibility test.
Table I shows the resistance patterns of the strains using 
the conventional drug susceptibility method, according to 
patient category.  Approximately 10% of re-treatment patients 
enrolled in the study had previously failed treatment.  The 
highest proportion of MDR-TB was found in patients who had 
previously failed treatment (73.3%), while lower but substantial 
levels of MDR-TB were present in patients who had previously 
been cured (36.9%) or who had interrupted treatment (27.7%). 
Patients who had previously completed treatment had the 
lowest MDR rates in this population.  A substantially higher 
level of MDR-TB was obtained compared with the published 
data which estimated approximately 8% MDR-TB in previously 
treated cases.3
The FASTPlaque-Response test and conventional DST 
results are shown in Table II.  Overall, 314 specimens (202 
rifampicin-susceptible and 112 rifampicin-resistant) were 
culture-positive for M. tuberculosis complex and gave an 
interpretable conventional susceptibility test result (86.3%).   
The conventional susceptibility result was unavailable in a total 
of 50 specimens (13.7%). Nineteen specimens were culture-
negative (5.2%), 17 specimens were contaminated on culture or 
DST (4.7%), and 14 specimens gave invalid results because of 
insufficient growth on the DST control plate (3.8%).
Of the rifampicin-resistant strains, 95.5% (107/112) were also 
resistant to isoniazid (MDR), while 5 strains were isoniazid-
susceptible.  One hundred and ninety strains were rifampicin 
and isoniazid-susceptible, while 12 strains were isoniazid-
resistant and rifampicin-susceptible.  No non-tuberculosis 
mycobacteria (NTMs) were isolated from any of the specimens. 
For the FASTPlaque-Response test, 257 specimens (70.6%) 
gave interpretable results overall.  Assay controls were out 
of specification for 4 batches of tests, which led to results of 
18 specimens not being interpretable (4.9%).  In addition, 38 
specimens (10.4%) gave less than 100 plaques on the RIF– plate 
and 51 specimens (14.0%) were contaminated to such an extent 
that results could not be interpreted.
Table III shows the FASTPlaque-Response results compared 
with the conventional DST, subdivided according to smear 
grading (1+, 2+ or 3+). Of the specimens that were culture-
positive and had a conventional DST result, 72.9% (229/314) 
specimens gave interpretable results using the FASTPlaque-
Response test. Seventy-three per cent (65/89) of 3+ smear-
positive specimens, 78.3% (83/106) of 2+ smear-positives 
and 68.1% (65/89) of 1+ smear-positive specimens gave 
interpretable results. A further 28 specimens gave interpretable 
results on the FASTPlaque-Response test but were culture-
negative, contaminated or gave uninterpretable results using 
conventional DST.
LJ cultures took 29.5 ± 8.4 days (mean ± standard deviation 
(SD)) to become positive, with times ranging from 7 to 64 
days, and cultures on selective 7H11 medium took 17.9 ± 5.6 
days (mean ± standard deviation (SD)), ranging from 10 to 
39 days. Conventional DST took 21 days.  Therefore the total 
turnaround time for the conventional testing ranged from 28 
to 85 days, with a mean ± SD of 50.5 ± 8.4 days on LJ medium 
and 38.9 ± 5.6 days on selective 7H11 medium. FASTPlaque-
Response results were available in 2 days from receipt of the 
specimen in the laboratory.
Of the 31 specimens that had less than 100 plaques on the 
RIF- plate but had a positive culture and DST result, 96.8% 
(30/31) of the strains could be infected by the phage when 
tested from the positive culture.
Contamination of 14.0% (51/364) on the FASTPlaque-
Response test was much higher than anticipated from 
previous studies,9,13 and appeared to be related to growth of 
contaminants which occurred during storage of plates at room 
temperature for up to several days after the final overnight 
incubation but before reading plates. Contamination was also 
found in at least 1 of the 3 cultures inoculated in 42 specimens 
(11.5%), although contamination precluded a result being 
obtained by conventional susceptibility testing in only 19 
Pg 858-863.indd   860 8/30/07   9:36:48 AM
ORIGINAL ARTICLES
861
September 2007, Vol. 97, No. 9  SAMJ
Table I.  Drug resistance patterns of the Mycobacterium tuberculosis strains using the conventional proportion method 
according to patient category (N)
Patient category                 HSRS               HRRS               HSRR               HRRR              Total (N (%))
Previously cured (RC)  71  6  0  45  122 (38.9)
Treatment failure (RF)  6  1  1  22  30 (9.6)
Treatment interrupted (RI)  94  4  4  39  141 (44.9)
Previously completed treatment (RT) 19  1  0  1  21 (6.7)
Total (%)   190   12  5  107  314
    (60.5)  (3.8)  (1.6)  (34.1)  (100)
HS = isoniazid-susceptible; HR = isoniazid-resistant; RS = rifampicin-susceptible; RR = rifampicin-resistant.
Table III. Comparison of FASTPlaque-Response with indirect 7H11 proportion method susceptibility test results related to 
smear grading (1+ to 3+ smear-positive), unresolved data
            Indirect 7H11 proportion method
                 Resistant  Susceptible           Culture-negative Contaminated†     Invalid
FASTPlaque-Response  
3+ smear-positive (N = 97)
Resistant       29          2‡              0              0      0
Susceptible       0          34              2              2      0
RIF- < 100 plaques*      1          0              0              0      0
Contaminated       9          7              1              3      0
Assay control out of specification     2          5              0              0      0
2+ smear-positive (N = 125)
Resistant       25          1‡              1              1      1
Susceptible       4          53              2              1      4
RIF- < 100 plaques*      1          11              0              3      0
Contaminated       4          6              1              0      3
Assay control out of specification     0          1              2              0      0
1+ smear-positive (N = 142)
Resistant       29          1‡              3              2      0
Susceptible       0          51              5              3      1
RIF- < 100 plaques*      2          16              1              3      0
Contaminated       2          12              0              1      2
Assay control out of specification     4          2              2              0      0
*Less than 100 plaques obtained on the RIF- plates.
†Contaminated on either culture or 7H11 susceptibility test.
‡One 1+ smear-positive, one 2+ smear-positive and one 3+ smear-positive specimen had a mutation in the rpoB gene associated with rifampicin resistance.
RIF = rifampicin.
Table II.  Overall comparison of the FASTPlaque-Response test with the indirect 7H11 proportion method susceptibility test, 
unresolved results per specimen (N = 364)
     Indirect 7H11 proportion method
FASTPlaque-
Response     Resistant Susceptible Culture-negative   Contaminated†    Invalid‡ Total (%)
      
Resistant             83        4§                5   3               0                        95 (26.1)
Susceptible            4        138                12  6               2                      162 (44.5)
RIF- < 100 plaques*            4        27                4   3               0                        38 (10.4)
Contaminated            15        25                4   4               3                        51 (14.0)
Assay control out 
of specification            6        8                4   0               0                       18 (4.9)
Total (%)            112       202                 19  17               14                     364
             (30.8)       (55.5)                               (5.2)  (4.7)               (3.8)                 (100)
* Less than 100 plaques obtained on the RIF- plate.
† Contaminated on either culture or 7H11 susceptibility test.
‡ Invalid result on 7H11 method due to insufficient growth on 7H11 control plate.
§ Three of these specimens had mutations in the rpoB gene associated with rifampicin resistance.
RIF = rifampicin.
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specimens (5.2%), owing to contamination on all 3 cultures 
(data not shown).
Results of both the FASTPlaque-Response and conventional 
DST were available for 229 specimens (Table IV).  Sensitivity, 
specificity and overall accuracy of the test were 95.4% (95% CI: 
91.0 - 99.8%), 97.2% (95% CI: 94.5 - 99.9%) and 96.5% (95% CI: 
94.1 - 98.9%) respectively compared with conventional culture 
and DST (unresolved) in specimens for which both results were 
available. Calculation of the kappa statistic21 showed ‘almost 
perfect agreement’ (κ = 0.93) of the FASTPlaque-Response and 
conventional method in specimens for which interpretable 
results were available for both methods. 
Four discrepant results were obtained in which the 
FASTPlaque-Response test identified a strain as being 
resistant, whereas the indirect DST determined the strain to 
be susceptible. Repeat testing confirmed the original results 
of both methods. However, molecular testing reported that 
3 of the 4 strains had mutations that conferred rifampicin 
resistance. These 3 strains were therefore considered to be 
rifampicin-resistant, while the fourth strain was considered 
susceptible. In addition, 4 discrepant results were obtained in 
which the FASTPlaque-Response test gave a susceptible result 
whereas the indirect susceptibility test result was resistant.  
Molecular testing found mutations conferring rifampicin 
resistance in 3 of the strains.  Repeat indirect testing results 
agreed with the initial results in all cases.  These 4 strains were 
assumed to be true rifampicin-resistant cases.
Discussion 
MDR-TB is already impacting on TB control in South Africa.  
Treatment of MDR-TB uses more toxic and expensive drugs, 
for longer periods, and is less effective than treatment of 
drug-susceptible disease.  The cost of treating 1 case of MDR-
TB is up to 25 times the cost of treating 1 drug-susceptible 
case.5 Drug susceptibility testing is critical in the management 
of patients with MDR-TB.  However, conventional drug 
susceptibility methods have a slow turnaround time of 
weeks to months which hinders rapid decision making by 
clinicians.  MDR-TB patients who remain undetected will be 
infectious for longer, leading to further opportunity for disease 
transmission.22 
In this study FASTPlaque-Response, a rapid test for 
rifampicin resistance was compared with conventional DST in 
re-treatment TB patients, who are at increased risk of MDR-
TB.  The FASTPlaque-Response test showed good correlation 
with the conventional DST results in those specimens for 
which interpretable results were available.  The FASTPlaque-
Response test also identified 3 strains as being resistant that 
were susceptible by conventional DST but were found to be 
rifampicin-resistant by molecular testing.20 In 97% of cases 
(539/556 patients) a single specimen was tested per patient, 
but for 3% of patients (17/556) 2 specimens were included in 
the study.  This may affect the independence of the results, but 
since such a small percentage of patients submitted multiple 
specimens it is unlikely that substantial bias was introduced.
A limitation of the study was that all testing was performed 
by the same technologists and blinding of specimens did not 
occur.  However, the possibility of introducing bias is not 
expected to be substantial since the FASTPlaque-Response 
results were reported first and there was a substantial delay 
before results were reported for the conventional culture and 
DST. 
Results of the FASTPlaque-Response test were available in 
2 days from receipt of the specimen, a reduction of between 
26 and 83 days compared with conventional testing.  No 
specialised equipment is required to perform the test, which 
is an important consideration in high-burden countries where 
procurement and maintenance of equipment can be a hurdle to 
implementation of new technologies. The rate of contamination 
experienced in this study was significantly higher than in 
previous studies in South Africa9,13 although higher rates 
of contamination have been reported elsewhere.11 This was 
a limitation of the test in this study since only 70.6% of 
specimens yielded an interpretable result compared with 86.3% 
of conventional DST results.  
This contamination appeared to be owing to storage of 
some plates at room temperature in the laboratory for several 
days before reading results, during which time growth of 
contaminants obscured the results.  The recommendation that 
results should be read immediately after overnight incubation, 
or if necessary stored at 2 - 8oC, should reduce contamination to 
acceptable levels.  Furthermore, the inclusion of antimicrobials 
in the test medium has since been implemented and this has 
resulted in reduction in contamination and increase in the level 
of interpretable results to 87.8% in specimens up to 3 days old 
or 79.1% in specimens up to 14 days old.23 The phage was able 
to detect the majority of different TB strains. It is likely that the 
lack of interpretable results, because of low numbers of plaques 
in the drug-free sample, may be due to inhibitory substances 
present in the sputum and/or the metabolic state of the cells  
ex vivo.11,14
Table IV.  Comparison of FASTPlaque-Response test 
with indirect 7H11 proportion method susceptibility test, 
unresolved data per specimen (N = 229)
                 Indirect 7H11 proportion method
FASTPlaque-Response       Resistant         Susceptible         Total
Resistant                   83            4 *    87
Susceptible                    4        138  142
Total                   87        142  229
* Three of these specimens had mutations in the rpoB gene associated with rifampicin 
resistance.
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The FASTPlaque-Response test only determines the 
rifampicin resistance of TB, although MDR-TB is defined as 
resistance to at least rifampicin and isoniazid.  However, in 
this setting, rifampicin resistance was a good indicator of 
MDR-TB, with 95.5% of rifampicin-resistant strains also being 
isoniazid-resistant.  This is in agreement with data from other 
countries3 showing that rifampicin-resistance is often a good 
marker for multidrug resistance. This high level of correlation 
may be related to the exclusive use of fixed-dose combination 
tablets for first-line TB treatment in South Africa and therefore 
limited opportunity for effective monotherapy owing to non-
compliance with treatment.  The rate of MDR-TB in this group 
of patients was substantially higher than the overall rate 
estimated for the Eastern Cape.  This was likely because of 
inclusion of a TB referral centre as one of the study sites, from 
which the majority of the MDR-TB patients in the study were 
enrolled. 
The FASTPlaque-Response test was evaluated in AFB-
positive sputum specimens only, as currently recommended by 
the manufacturer.  AFB-positive patients are the most infectious 
cases and therefore are high priority in terms of early detection, 
allowing suitable infection control measures and initiation of 
appropriate treatment. Smear-negative specimens could first 
be cultured and then tested using the FASTPlaque technology 
as previously described,14 or using conventional culture-based 
susceptibility testing.  
The appropriate timing of DST has been highlighted by 
the Stop TB Working Group for MDR-TB24 as an important 
research focus for DOTS-Plus initiatives.  A high proportion of 
patients who go on to fail standard treatment have a positive 
sputum smear at 2 - 3 months (74%), while only a minority of 
patients who go on to be cured have a positive smear at that 
time.24 Delay in detection and appropriate treatment of MDR-
TB patients may also lead to acquisition of further resistance.4  
Use of a rapid screening test for rifampicin resistance such 
as FASTPlaque-Response could play an important part in 
the TB control programme.  Earlier detection of MDR-TB 
cases would allow appropriate management and therapy and 
could improve patient outcomes as well as reduce disease 
transmission.  
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